Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol : A Chemical Compound of Cannabis sativa Alexandre R. de Mello Schier, Natalia P. de Oliveira Ribeiro, Danielle S. Coutinho, Sergio Machado, Oscar Arias-Carrión, José A. Crippa, Antonio W. Zuardi, Antonio E. Nardi and Adriana C. Silva CNS & Neurological Disorders - Drug Targets, 2014, 13, 953-960 Abstract : Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review [...]
Lire la suiteEffects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder Charlotte Marie Pretzsch, Jan Freyberg, Bogdan Voinescu, David Lythgoe, Jamie Horder, Maria Andreina Mendez, Robert Wichers, Laura Ajram, Glynis Ivin, Martin Heasman, Richard A. E. Edden, Steven Williams, Declan G. M. Murphy, Eileen Daly and Gráinne M. McAlonan Neuropsychopharmacology, 2019, 0, 1–8; https://doi.org/10.1038/s41386-019-0333-8 Abstract : There is increasing interest in the use of cannabis and its major non-intoxicating component cannabidiol (CBD) as a treatment for mental health and neurodevelopmental disorders, such as autism spectrum disorder (ASD). However, before [...]
Lire la suiteCannabidiol: State of the art and new challenges for therapeutic applications Simona Pisanti, Anna Maria Malfitano, Elena Ciaglia, Anna Lamberti, Roberta Ranieri, Gaia Cuomo, Mario Abate, Giorgio Faggiana, Maria Chiara Proto, Donatella Fiore, Chiara Laezza, Maurizio Bifulco Pharmacology & Therapeutics, 2017, 175, 133-150 DOI : 10.1016/j.pharmthera.2017.02.041 a b s t r a c t Over the past years, several lines of evidence support a therapeutic potential of Cannabis derivatives and in particular phytocannabinoids. Δ9-THC and cannabidiol (CBD) are themost abundant phytocannabinoids in Cannabis plants and therapeutic application for both compounds have been suggested. However, CBD is recently emerging as a therapeutic agent in numerous pathological conditions [...]
Lire la suiteCannabidiol (CBD) le point sur la législation Publié le 11/06/2018 De nombreux produits présentés comme contenant du CBD sont récemment apparus sur le marché français. La MILDECA a piloté un groupe de travail interministériel afin de rendre publiques des informations juridiques et techniques validées par toutes les autorités concernées. Le cannabidiol (CBD) fait partie des composés actifs majeurs du cannabis, autrement appelé chanvre, au même titre que le delta-9-tétrahydrocannabinol (THC). Les tétrahydrocannabinols sont des substances inscrites sur la liste des stupéfiants3. Leur utilisation est donc strictement encadrée. De nombreux produits présentés comme contenant du CBD sont récemment apparus sur le marché français. [...]
Lire la suiteLe cannabidiol (épisode 2) http://addictovigilance.aphp.fr/2019/04/09/le-cannabidiol-episode-2/ 09/04/2019 Après l’épisode 1 sur le cannabidiol, le CEIP-A de Paris propose l’épisode 2 Une mise à jour des données sur le CBD a permis de mettre en lumière de nouvelles informations que nous souhaitons communiquer à travers l’épisode 2 de notre série d’articles sur le cannabidiol (CBD). Depuis le début du mois de décembre 2018 l’Epidyolex®, un médicament sous forme de solution buvable contenant du CBD dosé à 100mg/mL, est disponible en France. Il dispose d’une Autorisation Temporaire d’Utilisation (ATU) dans l’indication du traitement des convulsions insuffisamment contrôlées par les traitements actuels dans le syndrome de Lennox-Gastaut et dans [...]
Lire la suiteLe cannabidiol (épisode 1) http://addictovigilance.aphp.fr/2018/11/09/le-cannabidiol-episode-1/ 09/11/2018 Depuis plusieurs mois, de nombreux « coffee-shops » ont ouvert un peu partout en France : 120 selon les estimations de l’association Norml. Ce sont des boutiques où il est possible d’acheter et consommer du cannabis. En France, étant donné que le cannabis est illégal, les coffee-shops proposent des produits à base de cannabidiol, substance présente dans le cannabis, mais non nommément désignée dans la liste des stupéfiants en France. L’ouverture de ces coffee-shops suscite le débat et face à l’ampleur du phénomène, les autorités sanitaires (MILDECA, ANSM, etc…) ont apporté une clarification sur la règlementation de ces produits [1]. Norml: National [...]
Lire la suiteTranslational Investigation of the Therapeutic Potential of Cannabidiol (CBD) : Toward a New Age José A. Crippa, Francisco S. Guimaraes, Alline C. Campos, Antonio W. Zuardi Frontiers in Immunology, 21 september 2018. https://doi.org/10.3389/fimmu.2018.02009 Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experimental and clinical use of cannabidiol CBD in neuropsychiatry. Methods: A non-systematic search was performed for studies dealing with therapeutic applications of CBD, especially performed by Brazilian researchers. Results: CBD was shown [...]
Lire la suiteThe Endocannabinoid System and Cannabidiol’s Promise for the Treatment of Substance Use Disorder Yann Chye, Erynn Christensen, Nadia Solowij, and Murat Yücel Frontiers in Psychiatry, 19 February 2019, doi: 10.3389/fpsyt.2019.00063 Substance use disorder is characterized by repeated use of a substance, leading to clinically significant distress, making it a serious public health concern. The endocannabinoid system plays an important role in common neurobiological processes underlying substance use disorder, in particular by mediating the rewarding and motivational effects of substances and substance-related cues. In turn, a number of cannabinoid drugs (e.g., rimonabant, nabiximols) have been suggested for potential pharmacological treatment for substance dependence. Recently, cannabidiol [...]
Lire la suiteThe Association between Cannabis Product Characteristics and Symptom Relief Sarah S. STITH, Jacob M. VIGIL, Franco BROCKELMAN, Keenan KEELING, Branden HALL Scientific Reports - Nature, 2019, 9, 2712. Published online 2019 Feb 25. doi: 10.1038/s41598-019-39462-1 PMCID: PMC6389973 PMID: 30804402 Abstract Federal barriers and logistical challenges have hindered measurement of the real time effects from the types of cannabis products used medically by millions of patients in vivo. Between 06/06/2016 and 03/05/2018, 3,341 people completed 19,910 self- administrated cannabis sessions using the mobile device software, ReleafApp to record: type of cannabis product (dried whole natural Cannabis flower, concentrate, edible, tincture, topical), combustion method (joint, pipe, vaporization), Cannabis [...]
Lire la suiteClinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L. Boggs, Jacques D. Nguyen, Daralyn Morgenson, Michael A. Taffe and Mohini Ranganathan Neuropsychopharmacology. 2018 Jan; 43(1): 142–154. Published online 2017 Oct 18. Prepublished online 2017 Sep 6. doi: 10.1038/npp.2017.209 PMCID: PMC5719112 PMID: 28875990 Abstract The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for [...]
Lire la suite